An innovative, implantable device for the treatment of Benign Prostatic Hyperplasia (BPH)
Developing a new generation device that offers a superior alternative to existing BPH minimally invasive treatments. Unlike current treatments that are surgical in nature and therefore require certain level of recovery and carry a risk of complications, the Butterfly Medical device is non-surgical, can be delivered at the comfort of the physician’s office and offers immediate relief.
Next generation continuous endoscopic suturing for minimally invasive surgical procedures
Developing a novel atraumatic, non-ischemic continuous suturing device. The first surgical “sewing machine” for minimally invasive surgery, combining simplicity, strength and durability. A single action, automatic device that generates continuous laparoscopy / flexible endoscopy sutures based on threaded smart anchors whose unique design avoids ischemia and reduces tension on the tissue.
Provides closed-loop digital therapeutics for cognitive and mental health
Brainmarc’s patent-pending, neuro-marker powered therapeutic solutions have shown positive results in validation testing with hundreds of patients in studies worldwide. Brainmarc is now leveraging its clinically proven technology to build prescribed digital solutions for cognitive and mental disorders.
Pioneering Urine-Output (UO) Measuring Device for the ICU
A breakthrough solution for accurate and automatic UO measurement, with lower cost, less workload and improved patient safety.
Michael joined Alon Medtech as Chief Financial Officer in 2014. He has over 20 years of management experience in overall financial & commercial strategy, fund raising and capital allocation, M&A transactions, investor relations, governance and risk management. Michael is a Senior executive with vast experience in investing and managing high-growth technology companies, due diligence processes, post-acquisition integration and active management and control over global subsidiaries. He has extensive knowledge of business, legal and tax aspects relating to investments, management and control of portfolio companies in different fields.
Prior to joining Alon Medtech, Michael served as a Financial, Commercial and Operational executive in leading high-growth technology companies such as: Convergin, a provider of service broker platforms to mobile operators, acquired by Oracle; Hobart (Prof Shlomo Ben Haim’s investment group) specializing in active management of its health-care portfolio companies from startup stage through acquisition and IPOs; and Aura Investment a publicly traded investment company focused on early stage investments and active management of technology companies.
Michael has a B.A in accounting and business administration and a Master of Law (LL.M) from Bar Ilan University and is also an Israeli certified public accountant.
Experienced Chief Executive Officer with a demonstrated history of working in the medical device industry and Pharma industry. Skilled in the Cardio Vascular, Neurosurgery, Spine, Minimal invasive surgeries, Medical Devices, High Tech Home Care businesses. Strong background in strategy and business development in the Medtech and Biotech industry.
Judith currently serves as a board member at a number of startups. She is a partner at HM Medical Solution LTD.
Judith has been until recently Medtronic’s Israel CEO for more than 12 years and an executive management member of Medtronic BCEGI region. Before joining Medtronic, Judith held senior management positions at Teva Ltd
Develops novel micro clip applier devices for performing regular and advanced micro-laparoscopy
Our multi-clip devices are characterized by a diameter of less than 3 mm, longer clips; larger opening of the clip arms; better visibility of the clip and a secure closure. These features will render our devices superior over existing clip appliers and will make them an ideal tool for both, regular as well as advanced laparoscopy or endoscopy procedures such as: needlescopic surgery; single port surgery; NOTES; and robotic surgery.
Superior Dermal Fillers Using a Novel HA Crosslink
Hallura’s products are based on a radically new HA crosslinking technology, characterized by a low concentration of HA, very low crosslinking rates, and very high molecular weight of the HA chains, with no low molecular weight fragments.
Innovating Non-Invasive Skin Tightening With USBT™
Developed a unique platform for non-invasive skin treatment: Ultrasound Beam Technology – USBT™, distinctive from any other ultrasound technology on the market. An array of ultrasound transducers generates multiple beams of high frequency, high intensity ultrasound energy that penetrates into the skin with minimal divergence such that the energy doesn’t “spread out” as the beams penetrates into the tissue.
A novel aesthetic imaging technology
Developed and selling high resolution 3D scanner for aesthetic applications. Cherry’s hand-held device enables accurate 3D measurement of all areas using Real 3D™ imaging of body and face, generated in real time. The easy-to-use camera captures thousands of three-dimensional images of face and body from multiple field views and angles, all within a single one-click scan.
Non-contact Atrial Fibrillation ablation therapy with real-time procedure monitoring
Developing the world’s first stand-alone, non-contact guided ultrasound ablation for pulmonary vein isolation with integrated lesion monitoring capabilities. The company’s solution consists of an over-the-wire catheter with a propriatery ultrasound transducer positioned within the pulmonary vein ostium for rapid, non-contact circumfrential ablation with real-time lesion feedback capabilities.
Next-generation embolic protection device for transcatheter aortic valve implantation (TAVI)
The Filterlex embolic protection device is a filter covered Nitinol frame and filter pockets. Its unique structure diverts embolic particles in the aortic arch to the capturing part of the device, where they remain and are extracted with the device at the end of the procedure.
EEG-based neurological indices for realtime intra-procedure assessment of anesthesia and sedation levels.
Developing an intra-operative brain monitoring device based on EEG signals for use in the OR by anesthesiologists, to measure the effects of anesthesia and sedation.
The technology utilizes a unique task related algorithm based on two neurophysiological measurements attention and perception.
Preventing brain injury during anesthesia
Developing an intra-operative brain monitoring device based on EEG signals for use in the OR by anesthesiologists, to measure the effects of anesthesia and sedation. Such monitoring is critical in most surgeries to prevent (a) postoperative state of delirium and cognitive dysfunction resulting from excessive use of anesthetics, and (b) the prevention of insufficient anesthesia, exposing the patient to the possibility of being paralyzed yet fully aware of what is occurring during surgery.
A Transcatheter Tricuspid Valve Replacement (TTVR)
The Trisol valve is constructed out of nitinol frame with specially designed sail-like leaflet. Its unique design provides a comprehensive solution to Tricuspid Regurgitation and RV dysfunction.
Electrotherapy Devices for Treating Gastroesophageal Reflux Disease (GERD)
Developing a noninvasive device that is applied by the patient onto the abdomen skin at specific positions, the device electrically stimulates the abdomen muscles by a pair of electrodes with specific current wave forms, the electrical pulses generates abdomen muscles asymmetrical contractions. Those contractions generates forward and “fast back” displacement of the esophagus (via the stomach) causing the remaining materials creeping back to the stomach.
A Transcatheter Cardiac Implant Focused on Improving Ventricular Geometry
Developing a novel transcatheter cardiac implant to improve cardiac function in patients with heart failure and/or functional mitral regurgitation.
Robust, non-intrusive automatic monitoring and alerting system for vital signs, human activity and mobility
A novel sensing technologies that provides solution for contact free continuous monitoring of hospital patients, enabling early detection of patient deterioration and prevention. Contact free continuous monitoring can prevent never events like falls and Ulcer, identify respiratory and cardio events in real time, reduce ICU days and medical staff workload.
For the past twelve years Dr. Makover has managed venture capital investments in the biotech/ medical devices field (Tzina Bio-Perspective, Proseed VC). Previously she held senior management positions in life sciences companies focusing on drugs, diagnostics and tissue engineering.
Dr Makover holds a joint Ph.D degree in life sciences from Columbia University (USA) and Weizmann Institute of Science, (Israel) and did post- doctoral research at the Weizmann Institute in Israel. DR. Makover also holds an MBA degree from Bar-Ilan University.
Dr. Makover is serving as a director of the board of six companies including public traded ones.
Prof Asher Barzilai was a director at the Edmond and Lily Safra Children’s Hospital at the Chaim Sheba Medical Center at Tel HaShomer, between 2011-2019. Prof Barzilai, an expert in infectious diseases, is an associate clinical professor of pediatrics at Tel Aviv University’s Sackler Faculty of Medicine.
Prof Barzilai earned his MD from Tel Aviv University, Israel. He specialized in Pediatrics at Mt. Sinai Hospital in New York City. Prof Barzilai holds an MBA from the executive MBA program run jointly by Northwestern and Tel Aviv Universities.
Dr. Makover is serving as a director of the board of six companies including public traded ones
Haya works closely with the Alon Medtech Chairman, CEO and management team on business intelligence and strategy.
Prior to Alon Medtech, she was Marcom manager responsible for strategy, budget and execution at a prominent IT integration company; Account manager at a leading PR firm; and Legal intern at Herzog Fox & Neeman – Capital Markets and Securities Dep, worked with public companies in all Corporate and Securities Law matters, engaged in public and private offerings of securities, worked on M&A transactions.
Haya holds an LLB degree for Kiryat Ono Academic College.
Anat is overseeing the portfolio companies financial aspects including accounting, budget and tax. Anat has over 10 years experience in providing professional services across a broad range of finance areas.
Prior to Alon MedTech, Anat held senior finance positions for international cooperations, privately-held companies and Hi-Tech companies and also served as a professional department manager for over 8 years.
Anat is an Israeli certified public accountant and holds a B.A in Business Administration and Accounting and a M.B.A (Tax specialization) from the College of Management.
Handling all legal aspects of Alon Medtech Ventures and its portfolio companies including fundraising, corporate law, labor law, clinical trials, commercial transaction, regulatory review as well as advising board of directors and C level executives on ongoing day-to-day issues.
Etel has over 13 years of legal counseling experience starting from commercial litigation through in-house counseling.
Etel holds LL.B from The Interdisciplinary Center in Herzliya and LL.M from the Tel Aviv Berkeley Executive program.
Dr. Ruthie Amir graduated from Ben Gurion University Medical School in 1989. From 1996-2000, she completed her post-doctoral fellowship in the Department of Human Genetic, at Baylor College of Medicine, Houston, USA where she worked on the genetic basis of Rett Syndrome.
Between 200-2003 she completed a post-doctoral fellowship in the Department of Cell Biology, Faculty of Medicine, Technion.
From 2008-2017, she served as the director of clinical research and the head of the regulatory department of Syneron Candela. In 2018, Dr. Ruthie Amir joined Alon-Medtech Ventures as the chief medical officer
VP Business Development
Mr. Mansour focuses on singling out medical technology companies for investment. He examines the commercial feasibility of entrepreneurs’ projects and connects with university-based technology transfer companies to advance cooperative efforts. Mr. Mansour’s maintains a long-term commitment to the portfolio companies, assisting them with business development and keep supporting them after they have become independent.
Mr. Mansour has more than 12 years’ business experience with high-tech companies, with particular expertise in managing international customers. In his last position he served as account program manager at Comverse, where he was responsible for customers across Europe.
Mr. Mansour holds a BSc in Industrial Engineering and an MBA from the Ben-Gurion University of the Negev.
Dr Zilberstein is responsible for managing Alon Medtech. Her activities include choosing projects, advancing them into companies and guiding their scientific activity. Further, she assists in structuring marketing strategy and forges scientific and commercial ties with external groups. Dr. Zilberstein serves as chairman or board member of the boards of directors of incubator companies.
Dr Zilberstein has more than 20 years’ experience in the medical device industry; Vast experience in investments in the Healthcare and nanotech fields.
Prior to joining Alon Med-tech ventures she served as GM of Maayan Ventures, an early stage investment fund; an active director/chairperson of numerous early stage companies; CTO & BDD of several entrepreneurial medical oriented companies and technological incubators. Dr Zilberstein is the inventor of a several innovations, in the field of optical sensors and cancer therapy.
Dr Zilberstein holds a BSc in chemistry. MSc in chemical physics and PhD in life science, from the Weizmann Institute of Science, She has published numerous scientific articles.
Dr. Shimon Eckhouse is an inventor, active entrepreneur and investor in the field of medical devices and medical technology. Dr Eckhouse is the founder, owner and Chairman of Alon Medtech. At Alon, Dr Eckhouse takes an active role in choosing projects and accompanying portfolio companies to success. He serves as chairman or board member of the boards of directors of incubator companies, and will be involved in the technological and business aspects of the portfolio companies.
Until recently, Dr Eckhouse was the chairman of Syneron Medical Ltd. (Nasdaq ELOS) which he co-founded in 2001, On July 2017 Syneron Medical was acquired by APAX partners in a “Going private” transaction. Dr Eckhouse is also the chairman and co-founder of Epitomee medical Ltd., Rapid Medical Ltd., Opticul Diagnostic Ltd., C3D Ltd., RealView Ltd. , Theranica Ltd. Dr. Eckhouse was a co-founder of ColorChip and served as its chairman and CEO from 2001 to 2003. Dr. Eckhouse is a co-founder of Ventor Medical Technologies Ltd. and served as its Chairman until it was acquired by Medtronic in 2009 for $325M. Dr. Eckhouse is the co-founder of Starlet Derma Ltd. (Nanocyte). Dr Eckhouse was the founder, chairman and CEO of Lumenis (former ESC Medical Systems) from its inception in 1992 until 1999. He took the company public on Nasdaq in January of 1996 and raised more than $250M in 3 public offerings, the company reached a valuation of more than $1B returning to its investors more than X120 on their investment in the company.
Dr Eckhouse is the inventor of IPL (Intense Pulsed Light) technology which he brought to market in 1994 in ESC and is the most popular non-invasive energy based technology for a broad range of non-invasive medical aesthetic applications.
Dr Eckhouse holds a BSc in physics from the Technion – Israeli Institute of Technology and a Ph.D. in physics from the University of California at Irvine. He is the author of more than 60 US registered patents and a few hundred international patents and published more than 50 papers in leading refereed journals and conferences.